2nd Quarter - Report

BROWN RUDNICK LLP for APOTEX CORPORATION

Period 2nd Quarter 2018 Filed Jul 11, 2018 Signed by Henry W. Menn III

Official filing
Firm
BROWN RUDNICK LLP
Client
APOTEX CORPORATION
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

President's Fiscal Year 2019 Budget relating to 180-Day Exclusivity for Generic Drugs

LobbyistCovered position, as disclosed
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S. 2476-Expanding Access to Low Cost Generic Drugs Act.

LobbyistCovered position, as disclosed
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 974 (115th), H.R. 2212 (115th), S. 2476 (115th), H.R. 2051 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.